ArcticZymes Technologies Logo

ArcticZymes Technologies

ISIN: NO0010014632 | Ticker: AZT | LEI: 5967007LIEEXZXGR7K47
Sector: Health CareSub-Industry: Biotechnology
Country: Norway

About ArcticZymes Technologies

Company Description

ArcticZymes Technologies has a long history dating back to the late 1980s. Based in Tromsø, Northern Norway, we use access to the marine Arctic to identify new cold-adapted enzymes for use in molecular research, in vitro diagnostics and therapeutics. We focus on strong and reliable relationships with our business partners and commercial innovators around the world. Therefore, we are constantly striving to work at the highest level and not only meet but exceed the expectations of our partners.

Our no-compromises approach ensures that our enzymes are robustly and reproducibly manufactured to deliver highly consistent products you can rely on. Our product development, manufacturing, sales and marketing processes are therefore certified and in accordance to the ISO13485 quality standard.

Year founded

1990

Served area

Worldwide

Headquarters

Postboks 6463, 9294 Tromsø – Norway

Financial statements

Download as Excel
Line item in (nok) 01.01.2020 01.01.2021 02.01.2021 01.01.2022 02.01.2022 01.01.2023
Assets N/A 221,912,000.00 N/A 284,111,000.00 N/A 319,037,000.00
Noncurrent Assets N/A 47,140,000.00 N/A 50,692,000.00 N/A 49,792,000.00
Property Plant And Equipment N/A 3,058,000.00 N/A 12,302,000.00 N/A 15,444,000.00
Intangible Assets Other Than Goodwill N/A 420,000.00 N/A 1,790,000.00 N/A N/A
Other Intangible Assets N/A N/A N/A 1,790,000.00 N/A 9,236,000.00
Deferred Tax Assets N/A 33,143,000.00 N/A 20,522,000.00 N/A 11,239,000.00
Other Noncurrent Assets N/A 5,000.00 N/A N/A N/A N/A
Current Assets N/A 174,771,000.00 N/A 233,420,000.00 N/A 269,246,000.00
Inventories N/A N/A N/A 6,882,000.00 N/A 7,078,000.00
Current Trade Receivables N/A 10,575,000.00 N/A 20,281,000.00 N/A N/A
Other Current Receivables N/A 20,130,000.00 N/A 5,833,000.00 N/A N/A
Cash and cash equivalents 31,662,000.00 140,178,000.00 N/A 200,424,000.00 200,424,000.00 244,161,000.00
Equity And Liabilities N/A 221,912,000.00 N/A 284,111,000.00 N/A 319,037,000.00
Equity 46,476,000.00 196,330,000.00 1,010.00 31,120.00 N/A 31,120.00
Issued Capital N/A 48,335,000.00 N/A 50,371,000.00 N/A 50,571,000.00
Share Premium N/A 151,039,000.00 N/A 260,256,000.00 N/A 261,656,000.00
Additional Paidin Capital N/A N/A N/A 111,100,000.00 N/A N/A
Equity Attributable To Owners Of Parent N/A N/A N/A 244,845,000.00 N/A 284,736,000.00
Noncontrolling Interests N/A 1,966,000.00 N/A N/A N/A N/A
Liabilities N/A 25,582,000.00 N/A 39,266,000.00 N/A 34,301,000.00
Noncurrent Liabilities N/A 9,595,000.00 N/A 14,472,000.00 N/A 10,348,000.00
Current Liabilities N/A 15,987,000.00 N/A 24,794,000.00 N/A 23,953,000.00
Trade And Other Current Payables To Trade Suppliers N/A 3,456,000.00 N/A 5,795,000.00 N/A N/A
Current Dividend Payables N/A 1,159,000.00 N/A N/A N/A N/A
Other Current Liabilities N/A 9,004,000.00 N/A 15,902,000.00 N/A 14,628,000.00
Line item in (nok) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Contracts With Customers 93,449,000.00 127,970,000.00 136,971,000.00
Other Income 4,374,000.00 3,078,000.00 694,000.00
Changes In Inventories Of Finished Goods And Work In Progress -903,000.00 -2,993,000.00 -196,000.00
Raw Materials And Consumables Used 2,034,000.00 6,878,000.00 5,376,000.00
Employee Benefits Expense 34,564,000.00 46,781,000.00 59,185,000.00
Depreciation And Amortisation Expense 2,639,000.00 3,191,000.00 5,021,000.00
Profit Loss From Operating Activities 42,793,000.00 58,432,000.00 36,474,000.00
Finance Income 1,744,000.00 1,545,000.00 6,352,000.00
Finance Costs 2,128,000.00 975,000.00 N/A
Profit Loss Before Tax 42,409,000.00 -59,002,000.00 -42,142,000.00
Income Tax Expense Continuing Operations 33,143,000.00 -12,621,000.00 -9,283,000.00
Profit Loss From Continuing Operations 75,552,000.00 46,380,000.00 N/A
Profit Loss From Discontinued Operations 9,356,000.00 N/A N/A
Profit (loss) 84,908,000.00 46,380,000.00 32,860,000.00
Profit Loss Attributable To Owners Of Parent 83,119,000.00 46,380,000.00 N/A
Profit Loss Attributable To Noncontrolling Interests 1,789,000.00 0.00 N/A
Line item in (nok) 01.01.2020 01.01.2021 01.01.2022 01.01.2023 02.01.2022
Profit (loss) N/A 84,908,000.00 46,380,000.00 32,860,000.00 N/A
Adjustments For Decrease Increase In Inventories N/A 1,932,000.00 2,993,000.00 196,000.00 N/A
Adjustments For Increase Decrease In Trade Account Payable N/A N/A 9,207,000.00 1,476,000.00 N/A
Adjustments For Depreciation And Amortisation Expense N/A 9,954,000.00 3,191,000.00 N/A N/A
Adjustments For Sharebased Payments N/A 848,000.00 1,238,000.00 5,432,000.00 N/A
Adjustments For Fair Value Gains Losses N/A N/A -40,000.00 N/A N/A
Cash Flows From Used In Operating Activities N/A 46,739,000.00 74,970,000.00 58,094,000.00 N/A
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 66,759,000.00 29,000.00 N/A N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 1,912,000.00 10,035,000.00 4,791,000.00 N/A
Purchase Of Intangible Assets Classified As Investing Activities N/A N/A 1,563,000.00 7,641,000.00 N/A
Other Inflows Outflows Of Cash Classified As Investing Activities N/A 4,000.00 5,000.00 N/A N/A
Cash Flows From Used In Investing Activities N/A 64,851,000.00 11,564,000.00 12,432,000.00 N/A
Proceeds From Issuing Shares N/A N/A 1,600,000.00 1,600,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities N/A 3,074,000.00 2,202,000.00 3,025,000.00 N/A
Interest Paid Classified As Financing Activities N/A N/A 694,000.00 499,000.00 N/A
Other Inflows Outflows Of Cash Classified As Financing Activities N/A N/A 703,000.00 N/A N/A
Cash Flows From Used In Financing Activities N/A -3,074,000.00 3,160,000.00 1,924,000.00 N/A
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 108,516,000.00 60,246,000.00 43,738,000.00 N/A
Cash and cash equivalents 31,662,000.00 140,178,000.00 200,424,000.00 244,161,000.00 200,424,000.00

Please note that some sums might not add up.

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

NO0010014632

LEI

5967007LIEEXZXGR7K47

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Brussels

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.